trending Market Intelligence /marketintelligence/en/news-insights/trending/IBo7ouQJUYp0ZtTzsQNWrw2 content esgSubNav
In This List

Allergan, Richter bipolar depression drug meets main goal in phase 3 study

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Allergan, Richter bipolar depression drug meets main goal in phase 3 study

Allergan plc and Gedeon Richter Plc said the phase 3 trial of Vraylar for treating major depressive episodes associated with bipolar 1 depression met its main goal.

Results from the RGH-MD-54 study showed that the 1.5- and 3-milligram doses of the treatment, also known as cariprazine, worked better than placebo.

Vraylar was also well tolerated under the study.

Allergan plans to submit a supplemental new drug application to expand Vraylar's indication in the U.S., in the second half of 2018.

Vraylar was discovered and co-developed by Gedeon Richter and is licensed by Allergan in the U.S. and Canada.

Vraylar is already approved as a treatment of adult patients with manic or mixed episodes associated with bipolar 1 disorder as well as for adults with schizophrenia.